ZEGALOGUE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEGALOGUE (ZEGALOGUE).
ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.
| Metabolism | Dasiglucagon is metabolized via proteolytic degradation into smaller peptides and amino acids; CYP enzymes are not involved. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80%) and minor hepatic metabolism with biliary/fecal elimination (10-15%). |
| Half-life | Terminal elimination half-life is 5-7 hours in healthy adults; in hepatic impairment, half-life may be prolonged up to 12 hours, requiring dose adjustment. |
| Protein binding | Approximately 85% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-0.8 L/kg, indicating moderate tissue distribution with concentrations in tissues approximately 1.5 times plasma. |
| Bioavailability | Oral: 40-50% (due to first-pass metabolism); Intramuscular: 90-100%. |
| Onset of Action | Intravenous: Within 1-2 minutes; Intramuscular: 5-10 minutes; Oral: 30-60 minutes. |
| Duration of Action | Intravenous: 4-6 hours; Intramuscular: 6-8 hours; Oral: 4-6 hours. Duration may be extended in renal impairment. |
Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m2). Not recommended for use in patients with end-stage renal disease (eGFR <15 mL/min/1.73 m2) due to lack of data. |
| Liver impairment | No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A). Not studied in moderate or severe hepatic impairment (Child-Pugh class B or C); use not recommended in these patients. |
| Pediatric use | Not indicated for pediatric patients; safety and efficacy in patients <18 years have not been established. |
| Geriatric use | No specific dose adjustment required based on age alone. However, dosing should be cautious due to potential for decreased renal function or comorbidities; monitor renal function and volume status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZEGALOGUE (ZEGALOGUE).
| Breastfeeding | No data on presence in human milk; dasiglucagon is a peptide likely degraded in GI tract. M/P ratio not determined. Caution in breastfeeding; consider risk of infant exposure vs benefit of treating maternal hypoglycemia. |
| Teratogenic Risk | Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk cannot be excluded; use only if benefit outweighs risk. Fetal risks: potential for maternal hypoglycemia-induced fetal distress if not treated. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Pheochromocytoma","Insulinoma","Known hypersensitivity to dasiglucagon or any excipients"]
| Precautions | ["Risk of serious hypersensitivity reactions including anaphylaxis","May cause nausea and vomiting","Risk of hypoglycemia if used in patients with insulinoma or glucagonoma","May increase blood pressure and heart rate"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose and response to treatment. Fetal monitoring not required for acute use; in pregnant patients, consider fetal heart rate monitoring if maternal hypoglycemia severe. |
| Fertility Effects | No human fertility data. Animal studies: no effects on fertility or reproductive performance in rats at doses up to 40 times human exposure. |